Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107534 | 0.84 | TLR7 (0.48) | KDM4EAPAF1NSD2ALDH1A1GAA | |
| SCHEMBL2387792 | 0.80 | TLR7 (0.53) | TLR7 | |
| SCHEMBL2390794 | 0.79 | TLR7 (0.46) | TLR7 | |
| SCHEMBL20275365 | 0.79 | TLR7 (0.53) | TLR7 | |
| SCHEMBL4126699 | 0.79 | TLR7 (0.49) | TLR7 | |
| SCHEMBL2390075 | 0.78 | TLR7 (0.46) | KMT2ATLR7 | |
| SCHEMBL2391004 | 0.78 | TLR7 (0.49) | KDM4EAPAF1NSD2ALDH1A1GAA | |
| SCHEMBL4499265 | 0.78 | TLR7 (0.46) | TLR7 | |
| SCHEMBL12048710 | 0.78 | TLR7 (0.50) | MAPTKMT2ATLR7 | |
| SCHEMBL5532528 | 0.78 | TLR7 (0.48) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1728793-B1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-8969362-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2015-03-03 | — | — | US | disclosed |
| US-8969362-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2015-03-03 | — | — | US | disclosed |
| US-8969362-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2015-03-03 | — | — | US | disclosed |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-02-13 | — | — | US | disclosed |
| US-8575180-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2013-11-05 | — | — | US | disclosed |
| US-8575180-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2013-11-05 | — | — | US | disclosed |
| US-8575180-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2013-11-05 | — | — | US | disclosed |
| US-20110306610-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | ASTRAZENECA AKTIEBOLAG (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20110306610-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | ASTRAZENECA AKTIEBOLAG (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20110306610-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | ASTRAZENECA AKTIEBOLAG (SE) | 2011-12-15 | — | — | US | disclosed |
| US-8012964-B2 | 9-substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8012964-B2 | 9-substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8012964-B2 | 9-substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1728793-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306610-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | IFNAR1, IL5, IFNG | KDM4E 3167/4885APAF1 4200/4885NSD2 1167/4885 |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | IFNAR1, IL5, IFNG | KDM4E 3167/4885APAF1 4200/4885NSD2 1167/4885 |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | IFNAR1, IL5, IFNG | KDM4E 3218/4885APAF1 4232/4885NSD2 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.